無針ドラッグデリバリーデバイスの世界市場:予測及び分析 2020-2024

Technavioが発行した調査報告書(IRTNTR40749)
◆英語タイトル:Needle-free Drug Delivery Devices Market by Product and Geography - Forecast and Analysis 2020-2024
◆商品コード:IRTNTR40749
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年12月
◆ページ数:152
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。

本レポートは、無針ドラッグデリバリーデバイスの市場実態を調査・分析し、エグゼクティブサマリー、レポートの範囲、市場状況、市場規模、ファイブフォース分析、製品別(吸入器、経皮パッチ、ジェットインジェクター)分析、顧客状況、地域別状況、意思決定フレームワーク、市場の要因と課題、市場動向、企業状況、企業分析を掲載しています。
・エグゼクティブサマリー
・レポートの範囲
・市場状況
・市場規模
・ファイブフォース分析
・無針ドラッグデリバリーデバイスの世界市場:製品別(吸入器、経皮パッチ、ジェットインジェクター)
・顧客状況
・地域別状況
・意思決定フレームワーク
・市場の要因と課題
・市場動向
・企業状況
・企業分析
【レポートの概要】

Global Needle-Free Drug Delivery Devices Market: About this market
Technavio’s needle-free drug delivery devices market analysis considers sales from inhalers, transdermal patches, and jet injectors. Our study also finds the sales of needle-free drug delivery devices in Asia, Europe, North America, and ROW. In 2019, the inhalers segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the high incidence of asthma will play a significant role in the inhalers segment to maintain its market position. Also, our global needle-free drug delivery devices market report looks at factors such as the increasing prevalence of chronic disease, rising number of new product launches, and the growing number of strategic alliances. However, frequent product recalls, stringent regulations associated with drug-device combination products, and high costs associated with needle-free drug delivery devices may hamper the growth of the needle-free drug delivery devices industry over the forecast period.

Global Needle-Free Drug Delivery Devices Market: Overview
Increasing prevalence of chronic diseases
Chronic diseases such as diabetes, especially type 1 diabetes is on the rise. According to the OECD, in 2017, about 600 children per 100,000 children had type 1 diabetes in Finland. With growing pollution and respiratory infections, instances of asthma have also dramatically increased. Physicians use needle-free drug delivery devices to administer insulin to children with type 1 diabetes. These devices also prove to be quite effective in the immediate administration of asthmatic medications. Needle-free drug delivery devices administer drugs through the skin of patients either by using shock waves or as a pressure generated by gas or electrophoresis. With the increasing prevalence of various chronic diseases such as diabetes and asthma, the need for needle-free drug delivery devices is increasing, which will lead to the expansion of the global needle-free drug delivery devices market at a CAGR of over 4% during the forecast period.

Technological advances in needle-free drug delivery devices
The intense competition in the market is compelling vendors to invest in R&D to expand their product portfolios. They are developing innovative and advanced devices to administer regular medications for disease management. These devices facilitate the process of drug administration for the management of several diseases and health conditions. The integration of software with needle-free drug delivery devices helps patients to adhere to their regular regimen of medication and, at the same, allows physicians to analyze the condition of their patients and improve the management of chronic respiratory diseases, such as asthma. This development is expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global needle-free drug delivery devices market during the forecast period 2020-2024, click here.

Competitive Landscape
With the presence of several major players, the global needle-free drug delivery devices market is fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading needle-free drug delivery devices manufacturers, that include 3M Co., Antares Pharma Inc., Becton, Dickinson and Co., Enesi Pharma Ltd., GlaxoSmithKline Plc, Inovio Pharmaceuticals Inc., Mylan NV, Novartis AG, PharmaJet Inc., and Valeritas Holdings Inc.
Also, the needle-free drug delivery devices market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Value chain analysis
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2019
• Market size and forecast 2019-2024
• Market outlook
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Inhalers – Market size and forecast 2019-2024
• Transdermal patches – Market size and forecast 2019-2024
• Jet injectors – Market size and forecast 2019-2024
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2019-2024
• Europe – Market size and forecast 2019-2024
• Asia – Market size and forecast 2019-2024
• ROW – Market size and forecast 2019-2024
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Technological advances in needle-free drug delivery devices
• Research and funding for development of needle-free drug delivery devices
• Increasing government initiatives
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• 3M Co.
• Antares Pharma Inc.
• Becton, Dickinson and Co.
• Enesi Pharma Ltd.
• GlaxoSmithKline Plc
• Inovio Pharmaceuticals Inc.
• Mylan NV
• Novartis AG
• PharmaJet Inc.
• Valeritas Holdings Inc.
PART 14: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO


Exhibit 01: Global healthcare equipment market
Exhibit 02: Segments of global healthcare equipment market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Vendors: Key offerings
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2019
Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
Exhibit 10: Five forces analysis 2019
Exhibit 11: Five forces analysis 2024
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2019
Exhibit 18: Product – Market share 2019-2024 (%)
Exhibit 19: Comparison by product
Exhibit 20: Inhalers – Market size and forecast 2019-2024 ($ millions)
Exhibit 21: Rate of hospital admissions for asthma and COPD (number of people per 100,000 population)
Exhibit 22: Inhalers – Year-over-year growth 2020-2024 (%)
Exhibit 23: Transdermal patches – Market size and forecast 2019-2024 ($ millions)
Exhibit 24: Transdermal patches – Year-over-year growth 2020-2024 (%)
Exhibit 25: Jet injectors – Market size and forecast 2019-2024 ($ millions)
Exhibit 26: Jet injectors – Year-over-year growth 2020-2024 (%)
Exhibit 27: Market opportunity by product
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2019-2024 (%)
Exhibit 30: Geographic comparison
Exhibit 31: North America – Market size and forecast 2019-2024 ($ millions)
Exhibit 32: North America – Year-over-year growth 2020-2024 (%)
Exhibit 33: Europe – Market size and forecast 2019-2024 ($ millions)
Exhibit 34: Europe – Year-over-year growth 2020-2024 (%)
Exhibit 35: Asia – Market size and forecast 2019-2024 ($ millions)
Exhibit 36: Asia – Year-over-year growth 2020-2024 (%)
Exhibit 37: ROW – Market size and forecast 2019-2024 ($ millions)
Exhibit 38: ROW – Year-over-year growth 2020-2024 (%)
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Estimated cases of children with type 1 diabetes 2017 (per 100,000 children)
Exhibit 42: Product launch
Exhibit 43: Strategic alliances
Exhibit 44: Product recalls
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: M Co. – Vendor overview
Exhibit 52: M Co. – Business segments
Exhibit 53: M Co. – Organizational developments
Exhibit 54: M Co. – Geographic focus
Exhibit 55: M Co. – Segment focus
Exhibit 56: M Co. – Key offerings
Exhibit 57: M Co. – Key customers
Exhibit 58: Antares Pharma Inc. – Vendor overview
Exhibit 59: Antares Pharma Inc. – Business segments
Exhibit 60: Antares Pharma Inc. – Organizational developments
Exhibit 61: Antares Pharma Inc. – Geographic focus
Exhibit 62: Antares Pharma Inc. – Key offerings
Exhibit 63: Antares Pharma Inc. – Key customers
Exhibit 64: Becton, Dickinson and Co. – Vendor overview
Exhibit 65: Becton, Dickinson and Co. – Business segments
Exhibit 66: Becton, Dickinson and Co. – Organizational developments
Exhibit 67: Becton, Dickinson and Co. – Geographic focus
Exhibit 68: Becton, Dickinson and Co. – Segment focus
Exhibit 69: Becton, Dickinson and Co. – Key offerings
Exhibit 70: Becton, Dickinson and Co. – Key customers
Exhibit 71: Enesi Pharma Ltd. – Vendor overview
Exhibit 72: Enesi Pharma Ltd. – Business segments
Exhibit 73: Enesi Pharma Ltd. – Organizational developments
Exhibit 74: Enesi Pharma Ltd. – Key offerings
Exhibit 75: Enesi Pharma Ltd. – Key customers
Exhibit 76: GlaxoSmithKline Plc – Vendor overview
Exhibit 77: GlaxoSmithKline Plc – Business segments
Exhibit 78: GlaxoSmithKline Plc – Organizational developments
Exhibit 79: GlaxoSmithKline Plc – Geographic focus
Exhibit 80: GlaxoSmithKline Plc – Segment focus
Exhibit 81: GlaxoSmithKline Plc – Key offerings
Exhibit 82: GlaxoSmithKline Plc – Key customers
Exhibit 83: Inovio Pharmaceuticals Inc. – Vendor overview
Exhibit 84: Inovio Pharmaceuticals Inc. – Business segments
Exhibit 85: Inovio Pharmaceuticals Inc. – Organizational developments
Exhibit 86: Inovio Pharmaceuticals Inc. – Key offerings
Exhibit 87: Inovio Pharmaceuticals Inc. – Key customers
Exhibit 88: Mylan NV – Vendor overview
Exhibit 89: Mylan NV – Product segments
Exhibit 90: Mylan NV – Organizational developments
Exhibit 91: Mylan NV – Geographic focus
Exhibit 92: Mylan NV – Segment focus
Exhibit 93: Mylan NV – Key offerings
Exhibit 94: Mylan NV – Key customers
Exhibit 95: Novartis AG – Vendor overview
Exhibit 96: Novartis AG – Business segments
Exhibit 97: Novartis AG – Organizational developments
Exhibit 98: Novartis AG – Geographic focus
Exhibit 99: Novartis AG – Segment focus
Exhibit 100: Novartis AG – Key offerings
Exhibit 101: Novartis AG – Key customers
Exhibit 102: PharmaJet Inc. – Vendor overview
Exhibit 103: PharmaJet Inc. – Business segments
Exhibit 104: PharmaJet Inc. – Organizational developments
Exhibit 105: PharmaJet Inc. – Key offerings
Exhibit 106: PharmaJet Inc. – Key customers
Exhibit 107: Valeritas Holdings Inc. – Vendor overview
Exhibit 108: Valeritas Holdings Inc. – Business segments
Exhibit 109: Valeritas Holdings Inc. – Organizational developments
Exhibit 110: Valeritas Holdings Inc. – Key offerings
Exhibit 111: Valeritas Holdings Inc. – Key customers
Exhibit 112: Validation techniques employed for market sizing
Exhibit 113: Definition of market positioning of vendors



【掲載企業】

3M Co., Antares Pharma Inc., Becton, Dickinson and Co., Enesi Pharma Ltd., GlaxoSmithKline Plc, Inovio Pharmaceuticals Inc., Mylan NV, Novartis AG, PharmaJet Inc., and Valeritas Holdings Inc.

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 無針ドラッグデリバリーデバイスの世界市場:予測及び分析 2020-2024(Needle-free Drug Delivery Devices Market by Product and Geography - Forecast and Analysis 2020-2024)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆